[Edaily Reporter Kim Jinsoo ] The stock price of #Remedy, a portable X-ray company, rose sharply as the company posted explosive earnings growth. As Remedy continues to grow rapidly both domestically and internationally, it is expected to maintain steady growth going forward.

Bio Solution Co.,Ltd.(086820) The stock price also rose due to expectations surrounding the company’s entry into the Chinese market, which is garnering attention on the global stage. In contrast, SyntekaBio,Inc.(226330)’s stock price fell sharply following the refusal of an audit opinion.

Remedy’s Stock Price Rises on Surprise Earnings

According to KG Zeroin’s MP Doctor (formerly Marketpoint)

,

Remedy’s

stock price

closed at 13,590 won on the day, up 22.76% from the previous day. The rise in Remedy’s stock price is attributed to its surprise earnings.

Remedy posted consolidated revenue of 15.5 billion won and operating profit of 6.1 billion won in the first half of this year. This means the company surpassed last year’s total revenue of approximately 14.6 billion won in the first half alone. Operating profit was more than double the previous year’s annual profit of 2.8 billion won.

Remedy has developed and commercialized X-ray technology based on proprietary technology that enables low-dose, high-resolution, and compact devices. Most of Remedy’s revenue comes from its flagship product, the “Remex-KA6,” and its expansion into overseas markets is driving these results. Remedy is rapidly increasing sales through its overseas distribution network, which spans more than 45 countries. As revenue grows, the company is also benefiting from reduced fixed costs, enabling it to achieve an operating profit margin approaching 40%.

Growth in the Indian market is particularly notable. Remedy’s performance rose significantly last year after supplying portable X-ray units to the Central Medicines Supply Service (CMSS)’s National Tuberculosis Eradication Program (NTEP) in India. Furthermore, the company was selected as the sole technically qualified vendor in a tender by the Odisha state government last month, and it is expected to begin a full-scale push into the state government’s public procurement market.

Going forward, the company plans to actively expand not only into India but also into other low- and middle-income countries where tuberculosis is a significant social issue.

A Remedy official stated, “Tuberculosis itself is not a severe disease, but it becomes extremely dangerous if left untreated. Tuberculosis tends to be concentrated in low- and middle-income countries with high population densities,” adding, “The only way to prevent the spread of tuberculosis is through screening via X-rays. Since mass screenings are being conducted in high-burden tuberculosis countries, we are pursuing market entry there more aggressively.”

The strengths of Remedy’s products lie in their portability and price. The Remex-KA6 weighs approximately 2.5 kg, which is one-hundredth the weight of conventional X-ray equipment (250 kg). Priced at about one-tenth that of conventional X-ray machines, it has secured a competitive edge.

A Remedy official explained, “The Remex-KA6 is extremely portable, offering many advantages for tuberculosis screening. Furthermore, since it is significantly cheaper than existing products, there is no reason not to choose it.”

In addition, Remedy is proceeding with the acquisition of a second factory and the implementation of production automation to prepare for expanding global demand. The company plans to sustain long-term growth based on these initiatives.

A Remedy official stated, “Our first-half results demonstrate that our core technology and global distribution network are now delivering tangible results.”

Bio Solution Co.,Ltd.’s Stock Price ‘Surges’ on News of China Entry Bio Solution

Co

.,Ltd.’s stock price

rose more than 19% during the trading session compared to the previous day but later gave up some of those gains, closing up 8.7% at 7,250 won. The rise in Bio Solution Co.,Ltd.’s stock price is attributed to the company’s entry into the Chinese market, which accounts for a significant share of the global osteoarthritis (OA) treatment market.

According to Fortune Business Insights, the Chinese osteoarthritis (OA) treatment market is estimated to reach approximately $1 billion (1.41 trillion won) by 2025. This represents 9.6% of the global market, which is projected to reach $9.89 billion (13.96 trillion won) in 2025. China is considered one of the world’s largest markets for osteoarthritis (OA) treatments on a per-country basis.

Bio Solution Co.,Ltd. has paved the way for the entry of its osteoarthritis treatment, “CartiLife,” into the Chinese market through Hainan, a special economic zone in China. On the 13th of this month, Bio Solution Co.,Ltd. signed a partnership with the “Boao International Clinic,” located in the Boao Luqing International Medical Tourism Pilot Zone in Hainan Province, to introduce and administer CartiLife, and on the 14th, it began treating its first patient in China.

The Boao International Clinic is a Grade 3 general hospital equipped with inpatient and outpatient wings, an International Regenerative Medicine Research Center, and a VIP rehabilitation and convalescence area, boasting medical infrastructure on par with that of a mid-sized university hospital in South Korea.

As the scope of procedures in China expands, Bio Solution Co.,Ltd.’s royalty revenue will also increase. Once its China operations gain full momentum, the company’s financial performance is expected to improve rapidly.

In particular, this first patient treatment is significant as it marks the beginning of the accumulation of real-world clinical data generated from Chinese patients. Bio Solution Co.,Ltd. plans to systematically gather real-world evidence (RWE) in China by continuously tracking treatment progress, safety, and clinical outcomes following patient procedures.

In fact, as of July 2, 2026, according to an announcement by the Hainan Provincial Drug Administration, 27 pharmaceuticals and medical devices have already secured early approval and launch in China by utilizing RWE obtained from Luqing.

Bio Solution Co.,Ltd. stated, “We will strengthen operations across all areas—from local sales and marketing to manufacturing and quality control—to ensure that Cartilife establishes itself as a competitive treatment option in the Chinese regenerative medicine market and drives tangible revenue growth.”

SyntekaBio,Inc. Receives Disclaimer of Opinion… “Focusing on Normalization”

SyntekaBio,Inc.’s stock price plummeted to the daily lower price limit early in the trading session. It later recovered from the lower limit before the market closed, ultimately ending the day down 24.45% at 1,131 won. The decline in SyntekaBio,Inc.’s stock price is attributed to the “disclaimer of opinion.”

After the market closed on the 14th, SyntekaBio,Inc. disclosed that it had been notified by its auditor, Samjeong Accounting Firm, of a refusal to issue an audit opinion on its semi-annual report. Samjeong Accounting Firm refused to issue the audit opinion, stating that sufficient and appropriate audit evidence regarding the legitimacy of loan transactions and the verification of their intended use had not been obtained.

According to SyntekaBio,Inc., the reasons for the refusal of the audit opinion include limitations on the scope of audit procedures and supporting documentation. SyntekaBio,Inc. plans to work with external expert organizations to review the reasons for the refusal of the audit opinion on its interim report and to supplement the relevant procedures. Specifically, the company has formed a team of legal and accounting experts and has begun the process of providing explanations and making necessary corrections.

Separately, SyntekaBio,Inc. plans to focus on restoring normal business operations while continuing to secure data center contracts and advancing its AI-based new drug platform business.

A SyntekaBio,Inc. official stated, “We will resolve the audit issues swiftly and transparently and will do our utmost to enhance shareholder value and normalize business operations based on our order intake and sales performance.”